Phase 3 data show monoclonal antibodies provide long-term protection against COVID-19 – Community News

Phase 3 data show monoclonal antibodies provide long-term protection against COVID-19

A single dose of REGEN-COV, a combination therapy with monoclonal antibodies, reduced the risk of COVID-19 by 81.6% several months after a single dose. Myron Cohen, MD of the UNC School of Medicine, leads monoclonal antibody research as part of the NIH-sponsored COVID prevention network.

Regeneron Pharmaceuticals, Inc. announced additional positive results from a Phase 3 clinical trial conducted jointly with the National Institute of Allergy and Infectious Diseases (NIAID), investigating the use of a single dose of REGEN-COV® (1200 mg administered via 4 subcutaneous injections ) to prevent COVID-19 in uninfected individuals. The new analyzes show that REGEN-COV reduced the risk of contracting COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), comparing the previously reported risk reduction during the first month after dosing. maintained in The New England Journal of Medicine.

“Today’s new data shows how a single dose of REGEN-COV can help protect people from COVID-19 for many months after dosing,” said Myron S. Cohen, MD, who leads the monoclonal antibody efforts for NIH-sponsored COVID prevention network (CoVPN) and is director of the Institute for Global Health & Infectious Diseases at the University of North Carolina at Chapel Hill. “These results demonstrate that REGEN-COV has the potential to provide long-term immunity against SARS-CoV-2 infection, an outcome that is especially important for those who fail to respond to COVID-19 vaccines, including those who are immunocompromised. ”

Monoclonal antibody treatment uses lab-made antibodies designed to attach to the coronavirus to prevent it from entering cells.

Using an innovative trial design, researchers were able to demonstrate the impact of REGEN-COV in a high-risk household transmission (month 1, both pre- and post-exposure prophylaxis), as well as after the immediate risk of household infection decreased (months 2-8). , pre-exposure prophylaxis), when most infections were thought to have been acquired in the wider community.

REGEN-COV is currently authorized in the US to treat people at high risk of serious consequences from COVID-19 infection who are already infected (not hospitalized) or in certain post-exposure prophylaxis settings. In the US, REGEN-COV is not approved as a replacement for vaccination against COVID-19, or for pre-exposure prophylaxis to prevent COVID-19, or for use in patients hospitalized for COVID-19 or requiring oxygen therapy , or for people currently on chronic oxygen therapy due to an underlying comorbidity needing an increase in baseline oxygen flow due to COVID-19.

Read more about the results of this trial.